Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, issues a stockholder letter from Chief Executive Officer, Dr. Phillip Chan. Additional detail will be forthcoming in the Company's Q4 and Full Year 2020 earnings press release and Form 10-K, expected March 9, 2021.
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation in the 10th Annual SVB Leerink Global Healthcare Conference. Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will discuss the Company's progress and outlook with Danielle Antalffy, Managing Director, Medical Devices, Equity Research at ...
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, highlights the recent release from the United Kingdom's internationally renowned National Institute for Health and Care Excellence (NICE) of a Medtech Innovation Briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery.
If you want to know who really controls Cytosorbents Corporation ( NASDAQ:CTSO ), then you'll have to look at the...
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces the immediate appointment of David D. Cox, Ph.D., M.B.A., as Vice President – Global Regulatory Affairs.
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces that the Korean Ministry of Food and Drug Safety (KMFDS) has approved CytoSorb for all equivalent European Union (E.U.) approved indications, including the reduction of cytokine storm, the reduction of bilirubin in liver disease, the reduction of myoglobin i...
CytoSorb now immediately commercially available throughout North America for use in COVID-19 patients, and in a total of 67 countries worldwideMONMOUTH JUNCTION, N., Jan.
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, pre-announces preliminary unaudited fourth quarter 2020 and full-year 2020 results ahead of filing its Form 10-K.